G. Andre Turenne
Independent DirectorMr. G. Andre Turenne is President, CEO & Director of Matchpoint Therapeutics, Inc. Mr. G. Andre Turenne serves as Independent Director at Inventiva S.A since May 2024. He served as President, Chief Executive Officer and Director at Voyager Therapeutics, Inc. since July 16, 2018 until 2021. Mr. Turenne has proven leadership, strategic vision and a strong track record of commercial and business development experience including at Genzyme and Sanofi where he served as Sanofi’s Senior Vice President, Global Head of Business Development from November 2015 to March 2018 and licensing responsible for partnering activities across all of Sanofi’s business units including Sanofi Pasteur, Sanofi Genzyme, Diabetes-Cardiovascular, General Medicines and Consumer Health. He previously served as global head of strategy and business development at Genzyme following its acquisition by Sanofi from September 2012 to January 2015. Mr. Turenne has held senior leadership positions at the country level as general manager of Sanofi Genzyme Australia/New Zealand from January 2015 to November 2015 with P&L responsibility for that region and at the global franchise level as head of commercial operations for the Renal and Endocrinology division at Genzyme Corporation. Mr. Turenne began his career in industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, part of Ogilvy. He serves as a Director of Valerion Therapeutics, LLC. Mr. Turenne holds a Bachelor of Arts from Kalamazoo College and a Master of Business Administration from the Tuck School of Business at Dartmouth.
Positions
- Company NameInventiva S.A.Stock CodeIVAPositionIndependent DirectorColleagues
- AOAndrew ObenshainChief Executive Officer
- MPMark PruzanskiIndependent Chairman
- PBPierre BroquaCo-Founder
- JVJean VolatierExecutive VP Finance & Corporate Social Responsibility
- MZMartine ZimmermannExecutive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs
- JAJason A. CampagnaPresident of Research & Development and Chief Medical Officer
- JJJean-Louis JunienChairman of Scientific Advisory Board
- HCHeinz Christoph MaeusliIndependent Director
- CSCamilla SoenderbyIndependent Director
